Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.